Hormone Resistant Prostate Cancer Completed Phase 2 Trials for Abiraterone (DB05812)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01503229Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment